

1001007813

IFW
IFW

PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/819,813
	Filing Date	03/29/01
	First Named Inventor	Kendrup, John et al
	Art Unit	
	Examiner Name	
Total Number of Pages in This Submission	Attorney Docket Number	22912

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Technology Center (TC)
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	Remarks Revocation of Power of Attorney with New Power of Attorney and Change of Correspondence Address	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	David W. Osborne
Signature	
Date	05/03/04

CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.		
Typed or printed name	Denise Dyer	
Signature		Date 08/03/04

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**REVOCATION OF POWER OF ATTORNEY
WITH NEW POWER OF ATTORNEY AND
CHANGE OF CORRESPONDENCE ADDRESS**

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8 DATE OF DEPOSIT: <u>08/03/04</u> I hereby certify that this paper or fee (along with any paper or fee referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as first class mail on the date indicated above and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 <i>Alma Rys</i>
--

**SUBSTITUTE POWER OF ATTORNEY AND
CHANGE OF ADDRESS FOR CORRESPONDENCE**

The undersigned, Watson Pharmaceuticals, hereby revokes all previous powers of attorney and all previous counsel for the matters identified herein and hereby appoints as its attorneys and/or patent agents the law firm of THORPE NORTH & WESTERN, LLP, having a business address of 8180 South 700 East, Suite 200, Sandy, Utah 84070, and VAUGHN W. NORTH, Registration No. 27,930; M. WAYNE WESTERN, Registration No. 22,788; CLIFTON W. THOMPSON, Registration No. 36,947; GARRON M. HOBSON, Registration No. 41,073; PETER M. DE JONGE, Registration No. 47,521; WEILI CHENG, Registration No. 44,609; DAVID R. MCKINNEY, Registration No. 42,868; STEVE M. PERRY, Registration No. 45,357; GARY P. OAKESON, Registration No. 44,266; DAVID W. OSBORNE, Registration No. 44,989; JASON R. JONES, Registration No. 51,008; ERIK S. ERICKSEN, Registration No. 48,954; JOHN W.L. OGILVIE, Registration No. 37,987; CHRISTOPHER L. JOHNSON, Registration No. 46,809; NATHAN S. WINESETT, Registration No. 55,733; TODD B. ALDER, and Registration No. 54,598; ALEX HAYMOND, with full power of substitution and revocation, to prosecute applications and to transact all business in the Patent and Trademark Office connected with regard to the following:

<u>TITLE</u>	<u>APPLICATION DATE</u>	<u>PATENT/APPLICATION NO.</u>
Zoem (Erodix)	02/21/01	09/788414
Aquapor Technology	03/29/01	09/819813
Zoem (Erodix)	01/15/03	10/342222
NAPDES	02/20/03	10/372045
Membrane coated sustained release tablets and method	09/05/84	4,557,925
Membrane coated sustained release tablets and method	12/16/86	4,629,619
Membrane coated sustained release tablets and method	09/19/85	4,629,620
Controlled Release Medical Preparations	09/25/85	4,824,678
Slow Release Formulation	02/09/87	4,880,830
Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents	8/31/88	4,925,677
Device for administering an active agent to the skin or mucosa	3/21/89	4,983,395
Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents	02/01/90	5,041,292

Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents	05/17/91	5,122,383
Apparatus and method for noninvasive blood glucose monitoring	06/02/89	5,139,023
Nifedipine-containing pharmaceutical compositions and process for the preparation thereof	01/30/90	5,145,683
Method and device for transdermally administering testosterone across a non-scrotal skin at therapeutically effective levels	02/07/91	5,152,997
Subsaturated transdermal drug delivery device exhibiting enhanced drug flux	12/11/90	5,164,190
Dosage Form	10/04/91	5,178,868
Methods and systems of administering nitroglycerine transdermally at enhanced transdermal fluxes	12/10/90	5,202,125
Sorbitan esters as skin permeation enhancers	04/21/92	5,212,199
Sorbitan esters as skin permeation enhancers	03/09/92	5,227,169
Methods and systems for administering nitroglycerine	07/24/92	5,302,395

transdermally at enhanced transdermal fluxes		
Appetite control method	03/28/91	5,336,486
Iontophoresis device and method using a rate controlling electrically sensitive membrane	10/15/92	5,445,607
Methods for providing testosterone and optionally estrogen replacement therapy to women	08/03/93	5,460,820
Controlled release morphine preparation	01/04/95	5,520,931
Pharmaceutical compositions containing nifedipine and process for the preparation thereof	07/11/94	5,594,013
Granular drug delivery system	09/13/95	5,641,511
Colonic delivery of drugs	06/07/95	5,656,294
Controlled release formulations for the treatment of xerostomia	04/01/91	5,686,094
Transdermal drug delivery matrix for coadministering estradiol and another steroid	07/19/96	5,783,208
Delivery of drugs to the lower GI tract	02/16/96	5,811,388
NSAID delivery employing a powdered hydrocolloid gum obtainable from higher plants	11/13/97	5,993,860


Purified galactomannan as an improved pharmaceutical excipient	06/07/95	6,063,402
Transdermal delivery system with adhesive overlay and peel seal disc	04/26/96	5,662,925
Dosage Forms & Methods for Oral Delivery Of Progesterone	12/28/1999	6,544,553
Dosage Forms & Methods for Oral Delivery Of Progesterone	02/24/2003	10/370,746
Skin Penetration Enhancement Using Free Base & Acid Add	12/19/1989	4,888,354
Protection Against Rhabdomyolysis-Induced Nephrotoxicity	02/25/1992	5,091,180
Assignment of U.S. Patent to Proctor & Gamble and Exclusive Royalty Free License Back to Theratech	01/16/1992	5,122,383

All correspondence concerning this application should be directed to:

M. Wayne Western
THORPE NORTH & WESTERN, LLP
Customer No. 28,122
P.O. Box 1219
Sandy, Utah 84091-1219
Telephone: (801) 566-6633
Facsimile: (801) 566-0750

Revocation Of Power Of Attorney
With New Power Of Attorney And
Change Of Correspondence Address
Page 6

Dated this 15th day of July 2004 at Salt Lake city, (City, State).
Utah
Watson Pharmaceuticals, Inc.

By: 
Phanesh Koneru
Vice President, Intellectual Property